[go: up one dir, main page]

FR2936255B1 - Modulateurs de fzd2 dans le traitement de l'alopecie - Google Patents

Modulateurs de fzd2 dans le traitement de l'alopecie

Info

Publication number
FR2936255B1
FR2936255B1 FR0856315A FR0856315A FR2936255B1 FR 2936255 B1 FR2936255 B1 FR 2936255B1 FR 0856315 A FR0856315 A FR 0856315A FR 0856315 A FR0856315 A FR 0856315A FR 2936255 B1 FR2936255 B1 FR 2936255B1
Authority
FR
France
Prior art keywords
alopecia
treatment
fzd2
modulators
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0856315A
Other languages
English (en)
Other versions
FR2936255A1 (fr
Inventor
Sandrine Rethore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0856315A priority Critical patent/FR2936255B1/fr
Priority to CA2737993A priority patent/CA2737993A1/fr
Priority to US13/120,103 priority patent/US20110224243A1/en
Priority to PCT/FR2009/051770 priority patent/WO2010031979A1/fr
Priority to EP09747890A priority patent/EP2329036A1/fr
Publication of FR2936255A1 publication Critical patent/FR2936255A1/fr
Application granted granted Critical
Publication of FR2936255B1 publication Critical patent/FR2936255B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0856315A 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie Expired - Fee Related FR2936255B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0856315A FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie
CA2737993A CA2737993A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie
US13/120,103 US20110224243A1 (en) 2008-09-19 2009-09-21 FZD2 Molulators in the Treatment of Alopecia
PCT/FR2009/051770 WO2010031979A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie
EP09747890A EP2329036A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0856315A FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie

Publications (2)

Publication Number Publication Date
FR2936255A1 FR2936255A1 (fr) 2010-03-26
FR2936255B1 true FR2936255B1 (fr) 2010-10-15

Family

ID=40568269

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0856315A Expired - Fee Related FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie

Country Status (5)

Country Link
US (1) US20110224243A1 (fr)
EP (1) EP2329036A1 (fr)
CA (1) CA2737993A1 (fr)
FR (1) FR2936255B1 (fr)
WO (1) WO2010031979A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133250A2 (fr) 2005-10-31 2007-11-22 Austin Gurney Compositions et procédés de diagnostic et de traitement du cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
EP2720721B1 (fr) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
WO2014066328A1 (fr) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
WO2014121196A1 (fr) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance de traitement par un inhibiteur de la voie wnt
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253012B2 (en) * 2000-03-31 2006-02-23 The General Hospital Corporation Methods of modulating hair growth
EP1743022A4 (fr) * 2004-02-27 2008-02-06 Gen Hospital Corp Procedes et compositions pour la croissance capillaire

Also Published As

Publication number Publication date
EP2329036A1 (fr) 2011-06-08
US20110224243A1 (en) 2011-09-15
CA2737993A1 (fr) 2010-03-25
WO2010031979A1 (fr) 2010-03-25
FR2936255A1 (fr) 2010-03-26

Similar Documents

Publication Publication Date Title
FR2936255B1 (fr) Modulateurs de fzd2 dans le traitement de l'alopecie
Lehoczky et al. Lgr6 marks nail stem cells and is required for digit tip regeneration
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
MX360620B (es) Anticuerpos anti kit y usos de los mismos.
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
MA34771B1 (fr) Formes cristallines
EP2209495A4 (fr) Taz/wwtr1 pour diagnostic et traitement de cancer
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
PE20121029A1 (es) Marcadores de riesgo para enfermedad cardiovascular
EP2257167A4 (fr) Inhibiteurs de la 2-aminoimidazole bêta-secrétase utiles pour le traitement de la maladie d'alzheimer
WO2012103165A3 (fr) Anticorps anti-kit et leurs utilisations
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
EP3839068A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
Hadjisavva et al. Adherens junctions stimulate and spatially guide integrin activation and extracellular matrix deposition
FR2904004B1 (fr) Modulateurs de scarb-1 dans le traitement de l'acne ou de l'hyperseborrhee
EA201290534A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов
Hutcheson et al. Elastogenesis correlates with pigment production in murine aortic valve leaflets
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
FR2936256B1 (fr) Modulateurs de lgr5 dans le traitement de l'alopecie
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2010020647A3 (fr) Nouveau procédé pour identifier des composés utilisés dans le traitement et/ou la prévention de maladies associées à la perte osseuse

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130531